perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 1 Management and outcomes of myelomeningocele-associated
- 2 hydrocephalus in low- and middle-income countries: a systematic

# 3 review and meta-analysis protocol

- 4 Berjo Dongmo Takoutsing<sup>1-2\*</sup>, Alvaro Yanez Touzet<sup>3\*</sup>, Jay J. Park<sup>4</sup>, Seong Hoon
- 5 Lee<sup>5</sup>, Emily R. Bligh<sup>6,7</sup>, Abdullah Egiz<sup>8</sup>, Conor S. Gillespie<sup>9</sup>, Anthony Figaji<sup>10-11</sup>, On
- 6 behalf of the Neurology and Neurosurgery Interest Group
- 7
- <sup>8</sup> <sup>1</sup>Faculty of Health Sciences, University of Buea, Buea, Cameroon
- 9 <sup>2</sup>Research Department, Association of Future African Neurosurgeons, Yaounde,
- 10 Cameroon
- <sup>11</sup> <sup>3</sup>School of Medical Sciences, Faculty of Biology, Medicine and Health, University of
- 12 Manchester, Manchester, United Kingdom
- <sup>4</sup>Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom
- <sup>5</sup>Academic Critical Care & Neurosurgery, Aberdeen Royal Infirmary, Aberdeen,
- 15 United Kingdom
- <sup>6</sup>Surgical Specialties, The Queen Elizabeth University Hospital, Glasgow, United
- 17 Kingdom
- <sup>7</sup>Academic Foundation Programme, The University of Glasgow, Glasgow, United
- 19 Kingdom
- 20 <sup>8</sup>School of Medicine, University of Central Lancashire, Preston, United Kingdom
- <sup>9</sup>Institute of Systems, Molecular and Integrative Biology, University of Liverpool,
- 22 Liverpool, United Kingdom
- <sup>10</sup>Division of Paediatric Neuroscience (Neurosurgery), School of Child and
- 24 Adolescent Health, University of Cape Town, Cape Town, South Africa
- <sup>11</sup>Red Cross Children's Hospital, Klipfontein Road, 7700 Rondebosch, Cape Town,
- 26 South Africa
- 27 Correspondence to: Alvaro Yanez Touzet;
- 28 <u>alvaro.yaneztouzet@student.manchester.ac.uk</u>
- 29 \*These authors contributed equally.
- 30
- 31 **PROSPERO registration number:** CRD42021285850
- 32
- 33 Wor: Chapter in a part of the search that has not been certified by peer review and should not be used to guide clinical practice.

#### 34 ABSTRACT

**Introduction:** Hydrocephalus and myelomeningocele (MMC) place disproportionate 35 burdens of disease on low and middle-income countries (LMICs). MMC-associated 36 hydrocephalus and its sequelae result in a spectrum of severely devastating clinical 37 manifestations, for which LMICs are disproportionately unprepared in terms of human, 38 39 capital, and technological resources. This study aims to review and compare the management and outcomes of infant MMC-associated hydrocephalus in LMICs and 40 41 high-income countries.

42

Methods and analysis: This systematic review and meta-analysis will follow the 43 PRISMA 2020 guidelines. The following databases will be searched without 44 restrictions on language, publication date, or country of origin: EMBASE, MEDLINE, 45 The Cochrane Library, Global Index Medicus, African Journals Online, and SciELO. 46 All peer-reviewed studies of primary data reporting management and outcomes of 47 infant MMC-associated hydrocephalus will be included. Where high-quality 48 49 homogeneous studies exist, meta-analyses will be conducted to compare the management and outcomes of MMC-associated hydrocephalus 50 across 51 socioeconomic and geographic regions of the world. The primary outcome will be treatment failure of the first-line hydrocephalus treatment, which we defined 52 53 operationally as the performance of a second intervention for the same reason as the first. Secondary outcomes include time to failure, rates of mortality, and postoperative 54 55 complications.

56

57 Ethics and dissemination: Ethical approval was not applicable because this study does not involve human participants. Dissemination strategies will include publication 58 59 in a peer-reviewed journal, oral and poster presentations at conferences, and an interactive web application to facilitate interaction with the findings and promote the 60 discussion and sharing of findings on social media. 61

62

### PROSPERO registration number: CRD42021285850 63

64

Word count: 245 65

#### 66 **ARTICLE SUMMARY**

#### Strengths and limitations of this study 67

- This review focuses on multiple treatment modes of a well-defined disease 68 population. 69
- Six electronic databases that are commonly used across both high- and low-70 • income countries will be searched. 71
- 72 No restrictions on language, location, or publication date were placed during • 73 screening.
- Unpublished studies will not be sought. 74 •
- 75 The representativeness of the sample will rely on the quality of reporting of • 76 myelomeningocoele-associated hydrocephalus in the literature.
- Only one operational definition of treatment failure—'the performance of a 77 78 second intervention for the same reason as the first'-will be sought.
- 79 • An interactive web application dashboard will be developed to facilitate the transparent interaction with our methods and findings and promote scientific 80 81 discussion and scrutiny.
- 82
- **Keywords:** Systematic Review; Meta-Analysis; Hydrocephalus; Meningomyelocele; 83
- 84 Infant: Developing Countries: Outcome and Process Assessment, Health Care

85

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 86 **INTRODUCTION**

Hydrocephalus places a disproportionate burden of disease on low- and middle-87 income countries (LMICs) (1, 2). It affects approximately 1 in 1,000 infants worldwide, 88 but its incidence may exceed 200,000 cases per year in developing regions like sub-89 90 Saharan Africa (3). Myelomeningocele (i.e., meningomyelocele or open spina bifida; MMC) is a common and severe spinal aetiology and constitutes a significant proportion 91 of this population (4-6). Its prevalence also varies by geography but approximates 113 92 cases per 100,000 births in LMICs (7, 8), reaching 77–610 and 700 cases per 100,000 93 births in South Africa and Nigeria, respectively. These disorders result in a spectrum 94 of clinical manifestations, among which MMC-associated hydrocephalus is one of the 95 most common and debilitating (4, 9, 10). 96

97

In LMICs, the incidence of MMC-associated hydrocephalus is high and can affect as many as 75% of cases (11, 12). Times to diagnoses and treatment are often delayed in these settings and, if treatment is not promptly initiated, most patients do not survive beyond infancy (4). Treatment may involve surgery, which is prone to significant morbidity and mortality, particularly in low-resource settings (1, 3). Intervening at the earliest stage with the best possible treatment remains, therefore, a crucial step in the management of MMC-associated hydrocephalus.

105

Ventriculoperitoneal (VP) shunts are the current standard of treatment in LMICs (1). 106 107 Increasingly, patients are being treated with endoscopic third ventriculostomy (ETV) or combinations of ETV and choroid plexus cauterization (CPC), whose success rates 108 109 and perceptions are variable (1, 3, 4, 9). Although ETV/CPCs were first developed and 110 validated in LMICs as the primary management for MMC-associated hydrocephalus, 111 there remains limited aggregated data regarding their outcomes in the very countries these procedures were developed in. As such, the practice and outcomes of these 112 techniques in LMICs warrant systematic review and meta-analysis. Previous work has 113 examined the management and outcomes of hydrocephalus in HICs and LMICs (13, 114 14) albeit in unstratified medical subject headings (MeSH) age groups and aetiologies. 115 116

- 117 STUDY AIMS AND OBJECTIVES
- 118 **Aim**

- 119 This study aims to review and compare the management and outcomes of MMC-
- associated hydrocephalus in infants across countries and treatment modes. 120
- 121

#### **Objectives** 122

- 123 To review and compare:
- 1. The first- and second-line use of VP shunts, combinations of ETV and CPC, 124
- and conservative management; 125
- 2. The rates and times to treatment failure of VP shunts, combinations of ETV and 126 127 CPC, and conservative management; and
- 3. Measures of mortality and postoperative complications of VP shunts, 128 combinations of ETV and CPC, and conservative management. 129
- 130

### **Review questions** 131

- 132 Primary question:
- 1. What are the rates of failure of VP shunts, ETV, combinations of ETV and CPC, 133 134 and conservative treatments in infant MMC-associated hydrocephalus?
- 135
- 136 Secondary questions:
- 2. What are the most frequent first- and second-line treatments in the 137 138 management of infant MMC-associated hydrocephalus?
- 3. What is the time to failure of VP shunts, ETV, combinations of ETV and CPC, 139 140 and conservative treatments in infant MMC-associated hydrocephalus?
- 4. What are the mortality and postoperative complication rates of VP shunts, ETV, 141 142 combinations of ETV and CPC, and conservative treatments in infant MMCassociated hydrocephalus? 143
- 5. Are the management and outcomes of the MMC associated with the failure of 144 the hydrocephalus treatment? 145
- 146

Subgroup analyses by country and treatment mode are planned (further details in 147 148 **Methods** section). The primary outcome will be the rate of treatment failure of the firstline hydrocephalus treatment. Secondary outcomes include: time to failure, rates of 149 150 mortality, and postoperative complications. Operational definitions of outcomes are provided in the Methods. 151

152

Due to its historical standing as the local standard of treatment, our principal 153 154 hypothesis is that:

- H<sub>1</sub>: VP shunts have the lowest rates of treatment failure in the infant MMC-155 156 associated hydrocephalus population.
- 157
- 158 Secondary hypotheses include:
- H<sub>2</sub>: VP shunts are the most frequently used first-line treatment and have the lowest 159 mortality and complication rates. 160
- 161 H<sub>3</sub>: Resource constrained environments are associated with late/worse MMC 162 presentation amongst infants
- H<sub>4</sub>: Late/worse MMC presentation is associated with high MMC treatment failure, 163 164 mortality, and complication rates.
- H<sub>5</sub>: MMC complication rates are associated with hydrocephalus treatment failure, 165 166 mortality, and complication rates.
- 167

### 168 METHODS

This systematic review will be conducted following the guidelines outlined by the 169 170 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 171 2020 statement (15).

172

### 173 Search

174 A search strategy was developed to identify research articles on MMC-associated hydrocephalus. This was adapted from McCarthy et al., 2019, and consisted of 175 176 synonyms of 'hydrocephalus' and 'myelomeningocele' (Supplementary Table 1). The search was run on the following electronic databases, from inception until 5 177 October 2021: EMBASE, MEDLINE, The Cochrane Library, Global Index Medicus, 178 African Journals Online, and ScieLO. No restrictions on language, location, or 179 publication date were placed, and unpublished studies will not be sought. Searches in 180 all databases will be re-run prior to final analysis. 181

182

### Study selection 183

### Types of studies 184

We will include articles published in peer-reviewed journals with any of the following 185 designs: original research, trials, cross-sectional and cohort studies, multiple case 186

- reports (i.e., >1 case), and case series. Opinion pieces, comments, letters, guidelines, 187 editorials, single-case reports, reviews, meta-analyses, and qualitative studies will be 188 excluded, as well as articles published in non-peer-reviewed journals. 189
- 190

### 191 Country income level

We will include studies whose data were collected in low-, lower-middle-, upper-192 middle-, and high-income economies, according to the World Bank Country and 193 194 Lending Groups (16). Studies from high-income economies will be used as 195 comparators. Studies whose data cannot be traced to one particular country will be 196 excluded.

197

### Types of participants 198

All studies of infants aged 2 years or younger with a clinical or imaging diagnosis of 199 MMC-associated hydrocephalus will be included. Non-infants (i.e., >2 years) will be 200 201 excluded, as will infants with diagnoses of lipomyelomeningocoele, spina bifida 202 occulta, or unspecified spina bifida, regardless of association with hydrocephalus.

203

### 204 Types of interventions

Studies of infants who have undergone either surgical or conservative treatment for 205 206 hydrocephalus will be included. Surgical treatment includes VP shunting, ETV, combined ETV and CPC, combined VP shunting and ETV, and combined VP shunting, 207 208 ETV, and CPC. We defined conservative treatment as non-surgical medical or 209 pharmacological treatment. Studies of infants who underwent treatment for MMC, but 210 not hydrocephalus, will be excluded, as will patients who received neither surgical nor 211 conservative interventions.

212

### Types of outcome measures 213

We will include studies of primary data reporting measures of treatment failure. In this 214 review, treatment failure will be operationally defined as the performance of a second 215 216 intervention for the same reason as the first. Studies reporting measures of mortality, 217 morbidity, postoperative complications, and follow-up duration will also be included for 218 secondary analysis. Post-operative complications will be defined as the unfavourable result of an intervention that did not result in treatment failure, and mortality as either 219 220 'intra-operative', if death occurred during a procedure, or 'perioperative', if it occurred

within 30 days of surgery. For conservative treatments, mortality will encompassdeaths that occurred within 30 days of administration.

223

### 224 Outcomes

The primary outcome of our study will be the rate of treatment failure for the first-line hydrocephalus treatment. Secondary outcomes will include time to failure, rates of mortality, and postoperative complications.

228

### 229 Study selection

Search results will be uploaded to Rayyan (https://www.rayyan.ai) to facilitate deduplication and independent, blinded screening (17). First, titles and abstracts will be screened by two independent reviewers against the inclusion criteria, and the eligibility of the selected abstracts will be determined by reading the full texts. Unless otherwise stated, conflicts will be resolved through discussion and, where consensus cannot be achieved, through arbitration by the senior author (AF).

236

## 237 Data extraction

238 Two reviewers will independently extract and check the data extracted from the included studies using a standardised extraction proforma in Google Sheets 239 240 (Supplementary Table 2). Any disputes will be settled by a third reviewer (BDT, AYT, or AF). Data items will include information on study and sample characteristics: 241 242 vertebral level of MMC and aetiology of hydrocephalus; clinical presentation and method of diagnosis; treatment mode, timing, and follow-up; and primary and 243 244 secondary outcomes. If data is insufficiently provided in the full text, we will contact the corresponding author to request for the missing information and wait up to two 245 months for a response. Following correspondence, all available data will be reported 246 and studies with missing data will not be eligible for inclusion in the meta-analysis. All 247 data will be recorded and stored in a spreadsheet. 248

249

## 250 **Risk of bias assessment**

Included studies will be assessed for risk of bias by two independent reviewers of the
extraction team. Randomised studies will be assessed using Version 2 of the
Cochrane risk-of-bias tool for randomised trials (RoB 2) (18). Non-randomised studies
will be assessed using the ROBINS I tool (19). Risk of bias assessment will be used

during the analysis and results presented in terms of the primary and secondaryobjectives of this study.

257

### 258 Data analysis

Following extraction, data will be transferred to Python for analysis. Screening results will be presented using a PRISMA flow diagram. Study and sample characteristics will then be summarised using descriptive statistics; these may include: vertebral level of MMC; aetiology of hydrocephalus; method of diagnosis; treatment mode; indication for surgery (if surgical management); timing, and follow-up; and primary and secondary outcomes.

265

The use, failure, and mortality measures of VP shunts, combinations of ETV and 266 CPC, and conservative management will then be meta-analysed. Although meta-267 analyses are planned, these will only become apparent after data extraction is 268 269 complete. Publication bias will be assessed through the use of funnel plots and 270 Egger's test (20). If asymmetry is found in the funnel plot, the Trim-and-Fill method will 271 be used to account for any potential publication bias (21). The overall estimates and 272 95% confidence intervals will be obtained using random-effects models as per established methods (22). Cochran's Q test (P < 0.10) and the I<sup>2</sup> statistic will be used 273 274 to assess heterogeneity among studies (23). Unless otherwise stated, the statistical significance will be set at P < 0.05, and comparisons to high-income economies will 275 276 be drawn.

277

278 Mortality, failure, and complication rates will however vary with hydrocephalus 279 aetiology, age, mode of treatment, characteristics of MMC, socioeconomic region and, 280 crucially, duration of follow-up. Therefore, subgroup analyses will be sought, as appropriate, and particular care will be taken when interpreting failure between shunt 281 placement and endoscopic treatments, owing to contrasting patterns of failure over 282 the shorter and longer terms. A combination of dichotomous, proportion, continuous, 283 284 O-E, and variance meta-analyses are planned for this purpose, as appropriate, depending on the data, and may include a potential subgroup analysis of the primary 285 286 outcome into short-term rates and long-term rates. Recognising that case reports may present unusual and/or protracted outcomes, and randomised trials may assess active 287 288 interventions improving outcomes, analyses by study design are also planned.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 289

### 290 Strength of body of evidence

- 291 The confidence in cumulative evidence included in this review will be assessed using
- the GRADE approach. Two independent reviewers will use the GRADEpro Guideline
- 293 Development Tool (GRADEpro GDT) to assess the quality of outcomes of this study.
- A third reviewer (BDT, AYT, or JJP) will settle disagreements.
- 295

## 296 Ethics and dissemination

Ethics approval for this study was not applicable because this study did not involve human participants. Dissemination strategies will include publication in a peerreviewed journal, oral and poster presentations at conferences, and an interactive web application to facilitate interaction with the findings and promote the discussion and sharing of findings on social media.

302

## 303 Patient and public involvement

- 304 None
- 305

## 306 ACKNOWLEDGEMENTS

307 We thank Moniba Korch, Brian Ou Yong Ming, and Safia Farsana Shabeer for their 308 contributions during the development and piloting of the extraction proforma.

309

# 310 AUTHOR CONTRIBUTIONS

BDT, AYT, and AF were responsible for conceiving the article. AF is the guarantor.

BDT, AYT, JJP, and CG wrote the manuscript. AE, AF, BDT, AYT, CG, ERB, JJP, and

- 313 SHL provided a critical appraisal of the manuscript. All authors critically revised and 314 approved the final manuscript. BDT and AYT contributed equally and are joint first
- authors of the manuscript.
- 316

# 317 ETHICS APPROVAL

318 Ethics approval for this study was not applicable because this study did not involve

- 319 human participants.
- 320

# 321 DATA AVAILABILITY STATEMENT

- All data relevant to the study are included in the article or uploaded as supplementary 322
- information. 323
- 324

### **FUNDING** 325

- 326 This work did not receive any funding.
- 327

### **COMPETING INTERESTS** 328

329 None declared.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

### 330 **REFERENCES**

331

332

Muir RT, Wang S, Warf BC. Global surgery for pediatric hydrocephalus in the
 developing world: a review of the history, challenges, and future directions. Neurosurg Focus.
 2016;41(5):E11.

Weiss HK, Garcia RM, Omiye JA, Vervoort D, Riestenberg R, Yerneni K, et al. A
Systematic Review of Neurosurgical Care in Low-Income Countries. World Neurosurg X.
2020;5:100068.

3. Kahle KT, Kulkarni AV, Limbrick DD, Jr., Warf BC. Hydrocephalus in children. Lancet.
2016;387(10020):788-99.

McCarthy DJ, Sheinberg DL, Luther E, McCrea HJ. Myelomeningocele-associated
 hydrocephalus: nationwide analysis and systematic review. Neurosurg Focus. 2019;47(4):E5.

343 5. Oumer M, Taye M, Aragie H, Tazebew A. Prevalence of Spina Bifida among Newborns
344 in Africa: A Systematic Review and Meta-Analysis. Scientifica (Cairo). 2020;2020:4273510.

345 6. Njamnshi AK, Djientcheu Vde P, Lekoubou A, Guemse M, Obama MT, Mbu R, et al.
346 Neural tube defects are rare among black Americans but not in sub-Saharan black Africans:
347 the case of Yaounde - Cameroon. J Neurol Sci. 2008;270(1-2):13-7.

348 7. Lo A, Polšek D, Sidhu S. Estimating the burden of neural tube defects in low- and
349 middle-income countries. J Glob Health. 2014;4(1):010402.

Zaganjor I, Sekkarie A, Tsang BL, Williams J, Razzaghi H, Mulinare J, et al. Describing
 the Prevalence of Neural Tube Defects Worldwide: A Systematic Literature Review. PLoS One.
 2016;11(4):e0151586.

353 9. Ntimbani J, Kelly A, Lekgwara P. Myelomeningocele - A literature review.
354 Interdisciplinary Neurosurgery. 2020;19:100502.

de Paul Djientcheu V, Njamnshi AK, Wonkam A, Njiki J, Guemse M, Mbu R, et al.
Management of neural tube defects in a Sub-Saharan African country: the situation in
Yaounde, Cameroon. J Neurol Sci. 2008;275(1-2):29-32.

11. Dewan MC, Rattani A, Mekary R, Glancz LJ, Yunusa I, Baticulon RE, et al. Global
hydrocephalus epidemiology and incidence: systematic review and meta-analysis. J
Neurosurg. 2018:1-15.

361 12. Mnguni MN, Enicker BC, Madiba TE. A perspective in the management of
362 myelomeningocoele in the KwaZulu-Natal Province of South Africa. Childs Nerv Syst.
363 2020;36(7):1521-7.

Ben-Israel D, Mann JA, Yang MMH, Isaacs AM, Cadieux M, Sader N, et al. Clinical
outcomes in pediatric hydrocephalus patients treated with endoscopic third ventriculostomy
and choroid plexus cauterization: a systematic review and meta-analysis. J Neurosurg Pediatr.
2022:1-13.

Pande A, Lamba N, Mammi M, Gebrehiwet P, Trenary A, Doucette J, et al. Endoscopic
third ventriculostomy versus ventriculoperitoneal shunt in pediatric and adult population: a
systematic review and meta-analysis. Neurosurg Rev. 2021;44(3):1227-41.

371 15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The
372 PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj.
373 2021;372:n71.

World Bank Data Help Desk. World Bank Country and Lending Groups 2022 [Available
 from: <u>https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-</u>
 <u>country-and-lending-groups</u>.

377 17. Rayyan – Intelligent Systematic Review 2022 [Available from: Rayyan. 378 https://www.rayyan.ai/.

379 Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a 18. 380 revised tool for assessing risk of bias in randomised trials. Bmj. 2019;366:14898.

Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. 381 19. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Bmj. 382 383 2016;355:i4919.

384 Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a 20. 385 simple, graphical test. Bmj. 1997;315(7109):629-34.

Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and 386 21. recommendations based on a large database of meta-analyses. Medicine (Baltimore). 387 388 2019;98(23):e15987.

389 22. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 390 1986;7(3):177-88.

391 23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-

392 analyses. Bmj. 2003;327(7414):557-60.

393